Robert M Straubinger Selected Research

Drug Combinations

2/2024	A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
1/2024	Systems pharmacodynamic model of combined gemcitabine and trabectedin in pancreatic cancer cells. Part I.Çô Effects on signal transduction pathways related to tumor growth.
10/2022	FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
11/2019	Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
1/2018	Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert M Straubinger Research Topics

Disease

43	Neoplasms (Cancer) 02/2024 - 05/2002
30	Pancreatic Neoplasms (Pancreatic Cancer) 02/2024 - 01/2013
12	Adenocarcinoma 02/2024 - 05/2013
6	Brain Neoplasms (Brain Tumor) 01/2017 - 05/2002
5	Hemophilia A (Haemophilia) 01/2012 - 04/2008
4	Glioma (Gliomas) 01/2017 - 01/2015
2	Breast Neoplasms (Breast Cancer) 03/2018 - 01/2013
2	Hemorrhage 01/2012 - 04/2008
2	Gliosarcoma 02/2010 - 05/2002
2	Ovarian Neoplasms (Ovarian Cancer) 11/2008 - 09/2002
1	Hyperthermia 10/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2019
1	Cardiotoxicity 03/2018
1	Infections 01/2017
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2016
1	Drug-Related Side Effects and Adverse Reactions 03/2014
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2013
1	Hepatocellular Carcinoma (Hepatoma) 05/2013

Drug/Important Bio-Agent (IBA)

16	Gemcitabine FDA Link 02/2024 - 09/2013
13	Paclitaxel (Taxol)FDA LinkGeneric 02/2024 - 09/2002
13	Liposomes (Liposome)IBA 01/2023 - 05/2002
7	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2018 - 05/2002
6	Proteins (Proteins, Gene)FDA Link 01/2024 - 07/2007
6	ProteomeIBA 12/2023 - 01/2013
6	birinapantIBA 10/2020 - 10/2015
5	Drug CombinationsIBA 02/2024 - 01/2018
4	TrabectedinIBA 01/2024 - 01/2016
4	Cetuximab (Erbitux)FDA Link 10/2023 - 11/2019
4	Drug CarriersIBA 10/2020 - 03/2004
4	Factor VIII (Coagulation Factor VIII)IBA 01/2012 - 04/2008
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2024 - 01/2021
3	ErbB Receptors (EGF Receptor)IBA 10/2023 - 08/2012
3	AntibodiesIBA 10/2023 - 11/2019
3	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 11/2019
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2023 - 05/2022
3	liposomal doxorubicin (Doxil)FDA Link 01/2023 - 12/2012
3	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 10/2020 - 10/2019
3	Antineoplastic Agents (Antineoplastics)IBA 03/2014 - 03/2010
3	Everolimus FDA Link 05/2013 - 01/2013
3	Sorafenib (BAY 43-9006)FDA Link 05/2013 - 01/2013
3	Phosphotransferases (Kinase)IBA 05/2013 - 08/2012
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 02/2024 - 11/2023
2	RNA (Ribonucleic Acid)IBA 02/2023 - 01/2017
2	130-nm albumin-bound paclitaxelIBA 01/2023 - 01/2018
2	CamptothecinIBA 10/2020 - 11/2019
2	Epidermal Growth Factor (EGF)IBA 03/2018 - 08/2012
2	Inhibitor of Apoptosis ProteinsIBA 01/2018 - 10/2015
2	MicellesIBA 01/2017 - 01/2016
2	TOR Serine-Threonine KinasesIBA 05/2013 - 01/2013
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2012 - 09/2010
2	Neutralizing AntibodiesIBA 01/2012 - 02/2011
2	PhosphatidylserinesIBA 02/2011 - 04/2008
1	Trifluridine (Viroptic)FDA LinkGeneric 02/2024
1	A-Form DNA (A-DNA)IBA 02/2024
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2024
1	IntegrinsIBA 01/2024
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2024
1	Complement Inactivating AgentsIBA 12/2023
1	Hyaluronic Acid (Hyaluronan)IBA 10/2023
1	Biomarkers (Surrogate Marker)IBA 10/2023
1	Monoclonal AntibodiesIBA 10/2023
1	MicroRNAs (MicroRNA)IBA 02/2023
1	ferric oxide (iron oxide)IBA 10/2022
1	Contrast MediaIBA 10/2022
1	folfirinoxIBA 10/2022
1	Fluorouracil (Carac)FDA LinkGeneric 10/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2022
1	auristatinIBA 11/2020
1	CaspasesIBA 10/2020
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 10/2020
1	Caspase 8 (Caspase-8)IBA 10/2020
1	DNA (Deoxyribonucleic Acid)IBA 10/2020
1	Ado-Trastuzumab EmtansineIBA 11/2019
1	sonidegibIBA 11/2019
1	Growth Factor ReceptorsIBA 11/2019
1	Capecitabine (Xeloda)FDA Link 01/2019
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 01/2019
1	Trastuzumab (Herceptin)FDA Link 03/2018
1	Insulin-Like PeptidesIBA 01/2018
1	Neuregulin-1 (Neuregulin 1)IBA 01/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018
1	histidine-rich proteinsIBA 01/2018
1	IstiratumabIBA 01/2018
1	Somatomedin Receptors (Somatomedin Receptor)IBA 01/2018
1	Small Nucleolar RibonucleoproteinsIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Epithelial Cell Adhesion MoleculeIBA 01/2017
1	Cocaine (Cocaine HCl)IBA 01/2016
1	LipidsIBA 01/2016
1	Cytotoxins (Cytolysins)IBA 10/2015
1	Cytostatic AgentsIBA 10/2015
1	Immunosuppressive Agents (Immunosuppressants)IBA 05/2013

Therapy/Procedure

17	Therapeutics 01/2023 - 03/2004
9	Drug Therapy (Chemotherapy) 02/2024 - 09/2002
4	Intra-Arterial Injections 01/2017 - 01/2015
3	Combination Drug Therapy (Combination Chemotherapy) 12/2023 - 04/2012
2	Lasers (Laser) 05/2022 - 10/2019
1	Aftercare (After-Treatment) 01/2023
1	Photochemotherapy (Photodynamic Therapy) 05/2022